PMID- 15813618
OWN - NLM
STAT- MEDLINE
DCOM- 20050621
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 28
IP  - 3
DP  - 2005 Mar
TI  - A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic 
      obstructive cardiomyopathy--the Baylor experience (1996-2002).
PG  - 124-30
AB  - BACKGROUND: There is a paucity of data on the long-term outcome of alcohol septal 
      ablation (ASA) for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). 
      HYPOTHESIS: The study was undertaken to evaluate the longer-term outcome of ASA 
      therapy for symptomatic HOCM. METHODS: In all, 137 patients were enrolled 
      consecutively (1996-1999) and 130 (95%) (74 men, 56 women, aged 51 +/- 17 years) 
      underwent ASA and had serial prospective follow-up for up to 5 years (mean 
      follow-up 3.6 +/- 1.4 years). Evaluation included angina (Canadian Cardiovascular 
      Society [CCS] score), dyspnea (New York Heart Association [NYHA] class), duration 
      of exercise on treadmill, and echocardiographic indices. RESULTS: Ethanol (3.5 
      +/- 1.5 cc), injected into 1.5 +/- 0.6 arteries, induced a mean peak plasma 
      creatine kinase (CK) of 1676 +/- 944 units. Complications of procedures included 
      death 1.5% (2/130), heart block requiring permanent pacemaker 13% (17/130), and 
      coronary dissection 4.4% (6/130). Baseline versus last follow-up visit: NYHA 
      class decreased from 3.0 +/- 0.4 to 1.2 +/- 0.6 (p < 0.01); CCS angina score from 
      2.0 +/- 0.8 to 0.08 +/- 0.4 (p < 0.01); and duration of exercise increased from 
      322 +/- 207 to 443 +/- 200 s (p < 0.01). Resting left ventricular outflow tract 
      gradient at baseline versus last follow-up visit showed a decrease from 74 +/- 30 
      to 4 +/- 13 (p < 0.01), and the dobutamine-provoked gradient of 88 +/- 29 
      decreased to 21 +/- 21 (p < 0.01) mmHg. All-cause mortality over the duration of 
      follow-up was 7.7% (10) giving an annual rate of 2.1%, and cardiac mortality was 
      2.3% (3) reflecting an annual rate of 0.6%. CONCLUSIONS: Alcohol septal ablation 
      decreased symptoms and improved exercise performance, indicating that it is an 
      effective procedure for symptomatic HOCM.
FAU - Fernandes, Valerian L
AU  - Fernandes VL
AD  - Section of Cardiology, Medical University of South Carolina, Charleston, South 
      Carolina 77030, USA.
FAU - Nagueh, Sherif F
AU  - Nagueh SF
FAU - Wang, Wei
AU  - Wang W
FAU - Roberts, Robert
AU  - Roberts R
FAU - Spencer, William H 3rd
AU  - Spencer WH 3rd
LA  - eng
GR  - P50-HL54313-07/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 3K9958V90M (Ethanol)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiomyopathy, Hypertrophic/mortality/*therapy
MH  - *Catheter Ablation/methods
MH  - Ethanol/administration & dosage
MH  - Exercise Tolerance
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Septum/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Ventricular Function, Left
PMC - PMC6654248
EDAT- 2005/04/09 09:00
MHDA- 2005/06/23 09:00
PMCR- 2006/12/05
CRDT- 2005/04/09 09:00
PHST- 2005/04/09 09:00 [pubmed]
PHST- 2005/06/23 09:00 [medline]
PHST- 2005/04/09 09:00 [entrez]
PHST- 2006/12/05 00:00 [pmc-release]
AID - CLC4960280305 [pii]
AID - 10.1002/clc.4960280305 [doi]
PST - ppublish
SO  - Clin Cardiol. 2005 Mar;28(3):124-30. doi: 10.1002/clc.4960280305.